Viewing nowPharma Empaglow 25 mg (Empagliflozin)
Empagliflozin 25mg
Tablet · Prescription medication
Korea Pharma Co., Ltd.

MFDS item code 202102824 · Approved 2021.03.31 · Insurance code 653007130
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps adults with type 2 diabetes control their blood sugar levels and is used in conjunction with diet and exercise. It can be used alone, but in cases where blood sugar control is difficult, it can be administered in combination with other diabetes medications such as Metformin, Pioglitazone, Sulfonylureas, Insulin, or Linagliptin. Caution should be taken when being used in patients with cardiovascular disease, referencing clinical trial information regarding cardiovascular events. This medication is effective for improving blood sugar control and is used effectively in diabetes treatment.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other blood glucose-lowering agents, such as insulin. If additional glycemic control is needed and 10 mg of this medicine is well tolerated, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose of this medicine, take it as soon as you remember. Do not take double the dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains below 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose of this medicine should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to less than 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older adults No dose adjustment is necessary based on age. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered. As clinical experience in older adults aged 85 years and older is limited, initiation of this medicine is not recommended (see Precautions for Use, 4. General Precautions).
This medication should not be given to certain patients. First, patients with allergic reactions to this medication's active ingredient or any of its components should not take it. Secondly, it is not to be used in patients with type 1 diabetes or diabetic ketoacidosis. Thirdly, patients with severely impaired kidney function, specifically those with a glomerular filtration rate of less than 30 mL/min/1.73m2, or those with end-stage renal disease or on dialysis should not take this medication. Fourthly, patients with genetic issues such as lactose intolerance or galactose intolerance should also avoid this medication. This medication should be used with caution in patients with mild kidney impairment. For those with a glomerular filtration rate of less than 60 mL/min/1.73m2, treatment initiation should be avoided, and if already on the medication, dosage adjustment or discontinuation may be necessary. It is not effective and not to be used in patients with end-stage renal disease or who are on dialysis. In patients with heart failure, especially mild to moderate cases, it should be used cautiously, and it is not recommended for those with severe heart failure. When combined with insulin or sulfonylureas, which stimulate insulin secretion, there is a risk of hypoglycemia, so dosage adjustments of these medications may be necessary. This medication may cause side effects including hypoglycemia, genital infections, increased urination, urinary tract infections, and decreased fluid volume. If any unusual symptoms appear, patients should consult a healthcare professional immediately. Especially, serious metabolic acidosis known as ketoacidosis may occur, so if symptoms such as nausea, vomiting, abdominal pain, or respiratory distress occur, patients should visit a hospital immediately. Elderly patients or those at risk of fluid loss should be cautious about dehydration and hypotension, and the administration of this medication may be temporarily suspended if necessary. This medication may affect kidney function, so regular kidney function tests are important. Additionally, it is advisable to avoid the use of this medication during pregnancy and to cease breastfeeding if currently nursing. Safety and efficacy have not been established for children and adolescents under 18, so it should not be used in these populations. No specific toxic reactions have been reported in cases of overdose, but appropriate treatment may be required based on clinical conditions. This medication may interact with other drugs, so patients taking other medications should inform their healthcare provider, especially when taking diuretics, insulin, or sulfonylureas. Finally, this medication should be kept out of reach of children, and it is safer not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a closed container to protect it from air and moisture. The appropriate storage temperature is room temperature between 1°C and 30°C. Avoid storing in excessively hot or cold places.
Light yellow, biconvex, oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Korea Pharma Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.